Berlex

AmeriNet's Elite Preferred® program is an innovative new program combining the influence of key members and the power of purchase commitment. The result is increased value and satisfaction for invited members.

With our recent effort in developing viable relationships with suppliers of MRI Contrast Media, these suppliers have taken center stage, providing quality the quality products and services. One such supplier is Berlex.


About Berlex

Committed to diagnostic imaging for more than 70 years, Berlex Laboratories has established a long tradition of bringing high quality, innovative imaging products to the healthcare marketplace.

Named a First Place Company Overall by Medical Imaging magazine's 2002 Readers' Choice Awards, and highly ranked in all categories, Berlex was lauded for excellence five categories:

  1. Quality of products introduced
  2. Price performance of products
  3. Product training
  4. Internal company leadership
  5. Product service and support

Over the years, Berlex products have revolutionized imaging technology with such efforts as the first paramagnetic MRI contrast agent, a world-class X-ray agent, and the first liver-specific MRI contrast agent. Berlex imaging product lines are focused and developed from new technologies from acquisitions as well as alliances and partnerships such as:

  • Partnering with sister company, Medrad®, a world leader in vascular injection systems and MR surface coils.

  • Forming an alliance with Abbott Laboratories to increase diagnostic imaging distribution capabilities.

  • Licensing agreements to market products, including FERIDEX I.V.® (ferumoxides injectable solution) which is a registered trademark of Advanced Magnetics Inc.

As a leader in the field, Berlex continually strives to satisfy the demand for new diagnostic and therapeutic agents giving clinicians everything they need and bringing high quality products and extensive professional and technical education programs to market.


Berlex Firsts

  • Magnevist® (gadopentetate dimeglumine), introduced in 1988, was the first IV contrast agent for use in magnetic resonance imaging.

  • Fludara® (fludarabine phosphate), the first therapy available for b-cell chronic lymphocytic leukemia cell, launched in 1992.

  • Betaseron® (interferon beta-1b), launched in 1993, the first interferon therapy for use in ambulatory patients with relapsing remitting multiple sclerosis to reduce the frequency of clinical exacerbation, a breakthrough for patients and their caregivers.

  • Climara® (estradial transdermal system), the first transdermal (patch) seven-day estrogen replacement therapy (ERT) product, launched in 1995.

  • Feridex IV® (fermoxides injectible solution), the first U.S. liver specific MRI imaging agent, launched in 1996.

  • Yasmin® (drospirenone and ethinyl estradiol tablets), the first and only oral contraceptive to contain the unique progestin, drospirenone, introduced in 2001.